BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024
January 25, 2024 01:00 ET
|
BioSenic
COMMUNIQUE DE PRESSE BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024 En utilisant une...
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
January 25, 2024 01:00 ET
|
BioSenic
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee...
Viscosupplementation Market Global Analysis and Forecast 2031 - Market Forecast to Surge in Valuation by 2031 with Single Injection Segment Leading Growth in North America and Asia Pacific Regions
December 28, 2023 05:28 ET
|
Research and Markets
Dublin, Dec. 28, 2023 (GLOBE NEWSWIRE) -- The "Viscosupplementation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application,...
Orthopedic Pain Management and Joint Reconstruction Lead Applications in the Expanding Orthopedic Regenerative Surgical Products Market
October 23, 2023 07:33 ET
|
Research and Markets
Dublin, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The "Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report By Product (Allografts, Viscosupplements), By End-use...
Global Viscosupplementation Markets Report 2022: A $8.958 Billion Market by 2030 from $4 Billion in 2021 - Surging Geriatric Populations and Prevalence of Osteoarthritis will Drive Market Growth
February 27, 2023 10:28 ET
|
Research and Markets
Dublin, Feb. 27, 2023 (GLOBE NEWSWIRE) -- The "Global Viscosupplementation Market, By Product Type, By End User, Estimation & Forecast, 2017-2030" report has been added to ...
Insights on the Orthopedic Regenerative Surgical Products Global Market to 2030 - Featuring Baxter, Zimmer Biomet and Allosource Among Others
April 21, 2022 06:48 ET
|
Research and Markets
Dublin, April 21, 2022 (GLOBE NEWSWIRE) -- The "Orthopedic Regenerative Surgical Products Market Size, Share & Trends Analysis Report by Product (Allograft, Synthetic, Cell-based,...
Bone Therapeutics annonce les résultats principaux de l'étude de Phase III évaluant son viscosupplément amélioré, le JTA-004, dans l'arthrose du genou
August 30, 2021 01:00 ET
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Aucune différence statistiquement significative n’a été observée dans la réduction de la douleur du genou entre JTA-004, le placebo et le comparateur actif 3 mois après le...
Bone Therapeutics announces topline results from Phase III knee osteoarthritis study with its enhanced viscosupplement JTA-004
August 30, 2021 01:00 ET
|
Bone Therapeutics SA
REGULATED INFORMATION No statistically significant difference in knee pain reduction between JTA-004, placebo and active comparator, 3 months after treatment; favorable JTA-004 safety profile...
Bone Therapeutics fait le point sur l’avancement de ses études cliniques
July 19, 2021 01:00 ET
|
Bone Therapeutics SA
INFORMATION RÉGLEMENTÉE Les premiers résultats de la phase III évaluant JTA-004 sont prévus pour la première moitié de septembre La phase IIb évaluant ALLOB est en cours malgré un...
Bone Therapeutics provides update on the progress of clinical studies
July 19, 2021 01:00 ET
|
Bone Therapeutics SA
REGULATED INFORMATION JTA-004 Phase III top-line results planned first half September ALLOB Phase IIb currently on track but recruitment slow due to COVID-19 pandemic Gosselies,...